Obesity

Subterms

    Latest story

    200 Shares111 Views

    Seth Meyers: ‘Trump has no idea what regular people are going through and he doesn’t care’

    by

    Late-night hosts discussed Donald Trump’s out-of-touch comments on grocery prices, the longest-ever government shutdown and a dramatic White House press conference on Ozempic.Seth MeyersSeth Meyers continued to analyze the results of Tuesday’s elections on Thursday evening, examining what fueled major victories for Democrats in Virginia and New Jersey. “If you do look inside the numbers, you’ll see that it wasn’t just anti-Trump backlash that fueled Democrats’ wins,” the Late Night host said. “Voters are also furious about the economy,” especially record-high grocery prices.“So the same thing that we were told was an issue in the last election was still an issue in this election because nothing has been fixed,” Meyers continued. “And voters are right – grocery prices are going up, everything from coffee to bananas to beef.” In fact, beef prices have never been higher. “Soon it’s going to get so bad that Trump’s going to start pushing Americans toward vegan options,” Meyers joked.But “don’t worry, Republicans, Trump is in touch with the common man,” he added. “That’s his gift. He knows what it’s like to go to the grocery store and feel the pain when you open your wallet and hand the cashier your ID and – wait, what?”Speaking from the White House, Trump claimed that “all we want is voter ID” at the grocery store. “You go to a grocery store, you have to give ID.”“Yeah, everyone knows you get carded at the grocery store,” Meyers deadpanned. “Trump has no idea what regular people are going through and he doesn’t care.”In fact, Trump insisted that grocery prices were going down in his recent interview with CBS News’s 60 Minutes. “You can lie about immigration, you can lie about the stock market, you can even lie about what wars you ended because most Americans will say ‘I didn’t even know that Thailand and Finland were at war,’” said Meyers. “But you can’t lie about the prices people see with their own eyes at the grocery store.”Stephen ColbertOn the Late Show, Stephen Colbert checked in on the government shutdown, now the longest in US history at 38 days. “The shutdown has already wreaked havoc on air travel, and that havoc is about to get even reekier,” he said, as air traffic controllers aren’t being paid and many aren’t showing up to work.So many, in fact, that the Federal Aviation Administration has directed airlines to cut 10% of their flights at the busiest airports. “So unfortunately it may be time to try your new favorite airline: the bus,” Colbert joked. “If you’re traveling for Thanksgiving, you might want to leave now.”Colbert also touched on the major victories for Democrats on election day, which Trump referred to in a press conference as “an interesting evening and we learned a lot”.“That sounds like what you’d say after a Tinder date where someone had to go to the hospital,” Colbert laughed.In other news, Fifa – “whose job, you’ll recall, is to take bribes and regulate soccer”, Colbert joked – announced a new peace prize to be awarded at the World Cup draw in Washington. “Yes, the Fifa peace prize: it’s given exclusively to world leaders who stop wars using only their feet,” Colbert said.“So it really looks like a made-up award just to give Trump something,” he noted, though when asked to confirm that Trump would be given the award, Fifa president Gianni Infantino demurred, saying: “On the 5th of December, you will see.”“Man, it is going to be hilarious when they give it to Obama,” Colbert laughed.The Daily ShowAnd on the Daily Show, Jordan Klepper recapped a dramatic White House press conference in which Trump announced a plan to cut the price of Ozempic and other pharmaceutical weight-loss drugs. “It’s all part of his campaign promise and his one consistent principle of ‘no fatties’,” Klepper joked.The press conference was “an event that turned into a major Hipaa violation”, as Trump announced the price cuts by singling out members of his administration who did or did not take weight-loss drugs.“Joking aside, obesity is a serious issue,” Klepper said. “So, this could be a benefit. Dr Oz, you’re a doctor, theoretically. Give us a reasonable expectation of success here.”Oz, the TV doctor turned Trump’s administrator for Medicare and Medicaid Services, boasted that Americans would “lose 135bn pounds by the midterms”.“Why the midterms?” Klepper wondered. “Did they add a swimsuit competition to those?“Look, I’m no mathematician,” he continued. “But 135bn pounds divided by 340 million Americans means we each have to lose … 400lb by the midterms. And I know that sounds like a lot, but remember: that’s just the average! Some people will lose 300lb, while other people will lose 500lb. Some of us will lose no pounds at all, which will be offset by everyone losing 800lb.“The point is, regardless of how much you lose, Donald Trump will be tracking it and announcing your personal results at a press conference.” More

    More stories

    • 138 Shares199 Views

      in US Politics

      Key takeaways: RFK Jr’s ‘Maha’ report on chronic disease in children

      by

      Donald Trump’s health secretary and long-time vaccine skeptic, Robert F Kennedy Jr, presented a highly anticipated report on children’s health this week.The “Maha commission” report, referring to the “Make America healthy again” movement, was required by a presidential executive order in February. The report focuses on chronic disease among children.The 68-page report broadly summarizes five areas affecting children’s health, with a focus on ultra-processed foods, environmental chemical exposure, lack of physical activity, “overmedicalization”, and “capture” of regulatory agencies.It notably omits some of the most common causes of chronic disease and death in children, insinuates there could be harms where there is lack of evidence, and avoids discussing how Republicans have already changed the health system in ways researchers believe are harmful.Art Caplan, a professor of bioethics at New York University’s Grossman School of Medicine, told the Guardian that the report has “interesting ideas about health and children’s health and crackpot fringe tin-hat-wearing nonsense – it’s got it all”.Here are five of the key takeaways from the report.1. The report ignores some common dangers to childrenThe most common causes of death among children are car crashes and firearm accidents. The report ignores these issues, as well as behaviors that often start in adolescence and lead to chronic disease in adulthood, such as smoking and alcohol use. It also criticizes water fluoridation, without mentioning its protective effects against cavities.Also, absent from the report is a discussion of how the administration has already changed the health department in ways that advocates argue will benefit industry and could exacerbate chronic disease.For instance, Kennedy eliminated two smoking prevention offices at the Centers for Disease Control and Prevention (CDC) and the Food and Drug Administration (FDA) in what one former regulator told Stat was “the greatest gift to the tobacco industry in the last half century”. He also eliminated a world-leading sexually transmitted infection laboratory.In another example, one of the nation’s leading researchers of ultra-processed foods quit his “dream job” after facing what he described as censorship from the administration (the health department reportedly asked him to return). In a similar vein, the Trump administration cut a program that delivered local whole foods to schools soon after taking office, in spite of Kennedy calling for healthier school meals.2. The report focuses on issues key to Kennedy’s view of healthThe report is roughly broken up into five sections focusing on ultra-processed foods, environmental chemical exposures, children’s mental health, “overmedicalization” and “corporate capture” of regulators by the industries they are supposed to oversee.Kennedy has harped on many of the issues listed in the report for months in public appearances and even though his defunct presidential campaign – especially including ultra-processed foods and obesity. Although some of these concerns may find bipartisan support – such as the focus on “forever chemicals” such as Pfas – it also pushes into areas where the science is unsettled.For instance, the report mentions that high levels of fluoride are potentially associated with reduced IQ, but does not mention its well-established protective effects against cavities – the most common chronic condition in children, according to the National Institute of Dental and Craniofacial Research.Similarly, the report argues that the childhood vaccine schedule is causing concern among parents for,“their possible role in the growing childhood chronic disease crisis” – without citing evidence that vaccines are linked to any specific chronic disease.3. It’s likely to face diverse pushback – and create new alliancesEven before the report was published, congressional lawmakers were being bombarded by calls from agricultural and chemical lobbyists wary of how the report would criticize their products – and indeed it did.One of the report’s sections questions whether “crop protection tools” including “pesticides, herbicides and insecticides” could harm human health. It then specifically name-drops glyphosate, the key ingredient in Roundup, and atrazine, a common herbicide. That is sure to make for strange political bedfellows and consternation within the Republican party. Similarly, the report cites synthetic dyes and ultra-processed foods are potentially harmful.Chemicals and food additives have been issues of concern for decades on the left. However, the Maha movement has also catalyzed opposition to them on the right.4. The report’s authors are not namedThe commission’s members are made up of the heads of intersecting agencies, including Kennedy at the Department of Health and Human Services, and the heads of the departments of agriculture, housing, education, veterans affairs and the Environmental Protection Agency, among others.However, the exact authors of the report are unknown. This contrasts with Kennedy’s repeated promise at his confirmation hearing that his health department would practice “radical transparency”.The work of the “Maha” commission was reportedly spearheaded by senior Kennedy adviser Calley Means, a former food lobbyist and healthcare entrepreneur who rose to prominence as a Maha truth-teller. Means co-wrote a bestselling book with his sister, current US surgeon general nominee Casey Means, which blames many of America’s ills on sedentary lifestyle and poor diet.5. Changing any of the issues identified is likely to be toughOne of the key issues the report identifies is the influence of food, pharmaceutical and chemical companies on American policy. They are monied and powerful.As a result, getting real change through Congress is certain to be tough – especially in an administration devoted to reducing regulations. More

    • 150 Shares199 Views

      in Elections

      Why Patients Are Being Forced to Switch to a 2nd-Choice Obesity Drug

      by

      CVS Caremark decided to stop offering Zepbound in favor of Wegovy for weight loss. It’s the latest example of limits imposed by insurance that disrupt treatments for patients.Tens of thousands of Americans will soon be forced by their health insurance to switch from one popular obesity drug to another that produces less weight loss.It is the latest example of the consequences of secret deals between drugmakers and middlemen, known as pharmacy benefit managers, that are hired by employers to oversee prescription coverage for Americans. Employers pay lower drug prices but their workers are blocked from getting competing treatments, a type of insurance denial that has grown much more common in the past decade.One of the largest benefit managers, CVS Health’s Caremark, made the decision to exclude Zepbound in spite of research that found that it resulted in more weight loss than Wegovy, which will continue to be covered.Those research findings, first announced in December, were confirmed in an article published on Sunday in The New England Journal of Medicine. The study involved a large clinical trial comparing the drugs that was funded by Eli Lilly, the maker of Zepbound. Earlier research not financed by Eli Lilly reached similar conclusions.Ellen Davis, 63, of Huntington, Mass., is one of the patients affected by Caremark’s decision. “It feels like the rug is getting pulled out from under my feet,” she said.After taking Zepbound for a year, she has lost 85 pounds and her health has improved, she said. She retired after working for 34 years at Verizon, which hired Caremark for her drug coverage.We are having trouble retrieving the article content.Please enable JavaScript in your browser settings.Thank you for your patience while we verify access. If you are in Reader mode please exit and log into your Times account, or subscribe for all of The Times.Thank you for your patience while we verify access.Already a subscriber? Log in.Want all of The Times? Subscribe. More

    • 163 Shares199 Views

      in Elections

      Patients Cut Off From Cheaper Obesity Drugs as FDA Halts Sales of Copycats

      by

      Hundreds of thousands of Americans stand to soon lose their access to cheaper weight-loss drugs, with a federal crackdown on copycat versions threatening to disrupt treatment and raise costs.The Food and Drug Administration has ordered producers and sellers of the less expensive products to wind down operations in the coming weeks now that it has declared there are no longer shortages of the blockbuster drugs Wegovy and Zepbound.Produced through a process of mixing drug ingredients known as compounding, the copycat medications had spawned a booming multi-billion-dollar industry. Patients turned to compounding because their health insurance would not pay for the brand-name drugs and they could buy the compounded versions for less than $200 a month in some cases.Eli Lilly and Novo Nordisk now offer the brand-name drugs for $500 a month in most cases to patients who pay with their own money instead of going through insurance. Until recently, patients sometimes had to pay over $1,300 a month.The F.D.A. ordered compounding for versions of Eli Lilly’s Zepbound to end last month. Small compounders have until April 22 to stop making and selling versions of Novo Nordisk’s Wegovy; large compounders have until May 22.It is not clear how the F.D.A. will enforce these deadlines. The Health and Human Services Department, which oversees the F.D.A., declined to answer questions for this article.We are having trouble retrieving the article content.Please enable JavaScript in your browser settings.Thank you for your patience while we verify access. If you are in Reader mode please exit and log into your Times account, or subscribe for all of The Times.Thank you for your patience while we verify access.Already a subscriber? Log in.Want all of The Times? Subscribe. More

    • 138 Shares149 Views

      in Elections

      How Much Should Weight Loss Drugs Like Wegovy and Zepbound Cost?

      by

      A new study found that fair prices for medications like Wegovy and Zepbound would be hundreds less per month than they are now.It’s easy to make a medical case for blockbuster weight loss drugs like Wegovy and Zepbound, which have been shown to prevent heart attacks and strokes and save lives.But for the employers and government programs being asked to pay for the medications, the financial case for them is less clear. Are the drugs’ benefits worth their enormous cost?The answer right now is no, according to a new study published on Friday in the journal JAMA Health Forum, by researchers at the University of Chicago.To be considered cost effective by a common measure used by health economists, the price of Novo Nordisk’s Wegovy would need to be cut by over 80 percent, to $127 per month, the researchers concluded. And Eli Lilly’s Zepbound would be cost effective only if its price fell by nearly a third, to $361 per month. (Zepbound warranted a higher price, the researchers said, because it produced greater benefits in clinical trials.)“There’s no doubt that the drugs are demonstrating tremendous health benefits,” said David Kim, a health economist at the University of Chicago and the senior author of the study, which was funded by government grants. “The problem is the price is too high.”There’s widespread hope that the drugs will effectively pay for themselves in the long run, by making patients healthier and preventing expensive medical bills. It’s not clear yet whether that will turn out to be true.We are having trouble retrieving the article content.Please enable JavaScript in your browser settings.Thank you for your patience while we verify access. If you are in Reader mode please exit and log into your Times account, or subscribe for all of The Times.Thank you for your patience while we verify access.Already a subscriber? Log in.Want all of The Times? Subscribe. More

    • 138 Shares169 Views

      in US Politics

      Biden proposes Medicare and Medicaid cover weight-loss drugs for 7.4m people

      by

      The Biden administration is proposing to make “miracle” weight loss drugs free for low-income people and retirees, in a move aimed at tackling America’s chronic obesity problem but which throws down a gauntlet to the incoming president, Donald Trump.The proposal, unveiled on Tuesday, would see expensive drugs such as Ozempic, Wegovy and Zepbound covered by Medicaid and Medicare, the federal government programs for the poor and the elderly.It would come at a hefty cost to the public purse. The drugs would be covered for anyone qualifying as obese, a definition that currently fits 40% of the US population. Currently, coverage is only given when patients have other conditions that is caused by obesity, such as diabetes, heart disease and cancer.Xavier Becerra, the US health and human services secretary, called the move a “game changer”.“It helps us recognize that obesity is with us,” he told the Washington Post. “It’s severe. It’s damaging our country’s health. It’s damaging our economy.”But the proposed reform amounted to a challenge to Trump’s incoming administration, which would have to decide whether to implement the change a few days after taking office in January. Trump has sworn to slash the federal budget.It also paved the way for a likely conflict between two of Trump’s health sector nominees: Robert F Kennedy Jr, who has been proposed as the health and human services secretary, and Mehmet Oz, the celebrity physician who has been nominated to run Medicare and Medicaid.Kennedy has vowed to promote healthy eating and improve fitness in the battle against obesity, and has fiercely criticised weight loss drugs, blaming them for obscuring the causes of ill health.He recently claimed to Fox News that covering a drug like Ozempic for every overweight American would cost $3tn a year.“If we spend about one-fifth of that, giving good food, three meals a day, to every man, woman and child in our country, we could solve the obesity and diabetes epidemic overnight for a tiny fraction of the cost,” he said.“There’s a huge push to sell this to the American public. They’re counting on selling to Americans because we’re so stupid and so addicted to drugs.”Oz has taken a different tack, praising Ozempic on social media last year. “[F]or those who want to lose a few pounds, Ozempic and other semaglutide medications can be a big help,” he wrote. “We need to make it as easy as possible for people to meet their health goals, period.”Beccera estimated that 3.4 million people on Medicare and 4 million on Medicaid would become eligible for the drugs under the new rule.But other research suggests that far more people may qualify. The Centers for Medicare and Medicaid Services (CMS), the agency Oz has been nominated to head, has estimated that 28 million recipients suffer from obesity.A recent Congressional Budget Office analysis estimated that federal spending would rise by $35bn between 2026 and 2034 by allowing Medicare alone to cover weight-loss medications.People can lose between 15% and 25% of their body weight thanks to the drugs, which imitate the hormones that regulate appetites. A month’s supply can cost around $1,000. More

    • 88 Shares149 Views

      in Elections

      Time to Say Goodbye to the B.M.I.?

      by

      The body mass index has long been criticized as a flawed indicator of health. A replacement has been gaining support: the body roundness index.Move over, body mass index. Make room for roundness — to be precise, the body roundness index.The body mass index, or B.M.I., is a ratio of height to weight that has long been used as a medical screening tool. It is one of the most widely used health metrics but also one of the most reviled, because it is used to label people overweight, obese or extremely obese.The classifications have been questioned by athletes like the American Olympic rugby player Ilona Maher, whose B.M.I. of 30 technically puts her on the cusp of obesity. “But alas,” she said on Instagram, addressing online trolls who tried to shame her about her weight, “I’m going to the Olympics and you’re not.”Advocates for overweight individuals and people of color note that the formula was developed nearly 200 years ago and based exclusively on data from men, most of them white, and that it was never intended for medical screening. Even physicians have weighed in on the shortcomings of B.M.I. The American Medical Association warned last year that B.M.I. is an imperfect metric that doesn’t account for racial, ethnic, age, sex and gender diversity. It can’t differentiate between individuals who carry a lot of muscle and those with fat in all the wrong places.“Based on B.M.I., Arnold Schwarzenegger when he was a bodybuilder would have been categorized as obese and needing to lose weight,” said Dr. Wajahat Mehal, director of the Metabolic Health and Weight Loss Program at Yale University.“But as soon as you measured his waist, you’d see, ‘Oh, it’s 32 inches.’”So welcome a new metric: the body roundness index. B.R.I. is just what it sounds like — a measure of how round or circlelike you are, using a formula that takes into account height and waist, but not weight.We are having trouble retrieving the article content.Please enable JavaScript in your browser settings.Thank you for your patience while we verify access. If you are in Reader mode please exit and log into your Times account, or subscribe for all of The Times.Thank you for your patience while we verify access.Already a subscriber? Log in.Want all of The Times? Subscribe. More

    • 200 Shares139 Views

      in US Politics

      Kamala Harris should launch a national campaign to end the US diabetes epidemic | Neil Barsky

      by

      Before addressing the political opportunity in front of the vice-president, let us first confront the sacred cow in the room.Contrary to recent claims by Donald Trump, JD Vance and Ted Cruz, Kamala Harris loves a good cheeseburger; she positively does not want to take our red meat away. She has cited sugars and sodas as major culprits in our poor health. Moreover, the Biden-Harris administration has demonstrated that it is unafraid to challenge the stranglehold the pharmaceutical industry has over insulin prices, and the cost that industry charges Medicare patients for drugs.Next, let’s dispense with the false narrative that Trump and his acolyte Robert F Kennedy Jr, have the capacity to “make America healthy again.” As part of RFK Jr’s recent endorsement, Trump vowed to appoint “a panel of top experts, working with Bobby, to investigate what is causing the decades-long increase in chronic health problems …” Kennedy, whose anti-vaccine work is more likely to make America have measles again, has recently become the darling of many metabolic health advocates for his series of half-truths about America’s obesity epidemic.Let’s not be fooled. To paraphrase Harris, these are not serious people, and the consequences of putting America’s healthcare in their hands would be deadly.I happen to live with type 2 diabetes, and have spent the past year chronicling the ways one of the country’s most lethal, expensive and ubiquitous diseases is actually reversible through a diet low in carbohydrates – the macronutrient that diabetics like me cannot safely metabolize without the help of drug therapies. Nutrition in America has become quite politically polarizing, as shaky science often collides with ideology, leaving us at a loss to know why we get fat, why we get sick, and even whether red meat causes diabetes (it doesn’t). Our healthcare budget is $4tn a year, yet our life expectancy is only 48th in the world, and we seem to be getting heavier and sicker. Something is terribly wrong.In this abyss lies a golden opportunity for presidential candidate Harris to present a healthcare agenda that would save thousands of lives, billions of dollars, as well as her appeal to voters in conservative states. She can do what no president has ever had the courage to do before: launch a national campaign to reverse America’s diabetes epidemic and, in the process, improve our metabolic health. She might even declare the destructive disease a national emergency.This initiative would be both good policy and good politics, and it is not as quixotic as it might first sound. Type 2 diabetes is a condition where the hormone insulin does not naturally function properly, leading to high blood sugars, and leaving its victims at risk of cardiovascular, kidney, eye and other disease. Currently, 38 million American adults have diabetes, while another nearly 100 million more have pre-diabetes – or more than a third of adult Americans. At $420bn per year, it is one of America’s costliest diseases, accounting for over 10% of the country’s $4tn annual healthcare budget. It kills over 100,000 Americans annually, more than die of opiate overdoses.And while it is true that people of color are more likely to get diabetes than white people, it is also the case that, like the opiate crisis, diabetes is a color-blind disease that has disproportionately ravaged red state America. In fact, 14 of the 15 states with the highest diabetes mortality rates voted Republican in 2020. And 14 of the 15 states with the lowest mortality rates voted Democratic in 2020.What form should a Harris initiative take? Here are my personal recommendations, based on my own experience with the disease, and a year’s worth of interviewing well over 100 researchers, clinicians, advocates and patients. Frankly, it is baffling that this disease – which is killing us widely, breaking our budget and reversible through diet – is not yet a matter of national urgency.1. First, she should announce her intention to appoint a diabetes czar whose job, among other things, would be to solve this puzzle – over the past quarter-century, America’s pharmaceutical and medical technology industry have made extraordinary strides developing various forms of insulin and other drugs, continuous glucose monitors and test strips. So why have seven times more Americans been diagnosed with diabetes than in 1980? Eventually commonsense solutions would emerge, such as restricting cereal companies’ ability to market their sugary treats to children.Not only would the czar be empowered to confront things like the scandalous $1bn-plus in sugar subsidies provided by US taxpayers, she would explore common-sense treatments for treating diabetes that are diet and lifestyle-focused. (A good place to start would be the excellent 2024 book Turn Around Diabetes, written by endocrinologist Roshani Sanghani.)2. We must defund, disqualify and otherwise delegitimize the American Diabetes Association (ADA). As I have written, the ADA has become a virtual branch of big pharma and big food. Yet it sets standards of care for clinicians and de-emphasizes mountains of evidence that the low-carbohydrate diet is a powerful tool in reversing the disease. Frankly, it is mind-boggling that the world’s most powerful diabetes-fighting organization (2023 revenue: $145m) has so utterly failed to stem the disease, but still sets standards of care, controls research dollars and dictates the diabetes narrative in this country.Late last year, the ADA was sued by its former director of nutrition. She claimed she was fired for refusing to include the artificial sweetener Splenda, whose parent company donated $1m to the ADA, in the ADA’s list of approved recipes. It is one of American healthcare’s great tragedies that the ADA and the plaintiff, Elizabeth Hanna, settled before the facts of the inner workings of the ADA were brought to light in a trial. In any case, the complaint is a stinging indictment of the organization and should be read by every clinician interested in learning how corporate donations have corrupted the organization’s nutrition guidance.3. Perhaps most urgently, the federal government, including the National Institutes of Health, should expand its research budget to include researchers treating patients with low-carbohydrate and ketogenic diets. Over the past two decades, there has been an explosion of courageous clinicians who prescribe the low-carbohydrate diet to their patients, as well as at least two startups – Virta Health and OwnaHealth – with promising results treating diabetes and obesity with low-carbohydrate diets.But because their research does not include the search for the next blockbuster drug, researchers often cannot access ADA, NIH and big pharma research dollars. They don’t get prominent spots in pharma-funded conferences. This is an enormous impediment to the low-carbohydrate diet becoming part of the medical mainstream and in my opinion is responsible for the persistence of the diabetes plague.4. We should give platforms to people who actually have diabetes, especially those who have reversed their condition by taking control of their diet. Of all the misconceptions I uncovered in my reporting on diabetes, the most common was that the low-carb diet was too difficult for patients, particularly low-income patients, to maintain. Of course, resisting bread, sweets, rice and starches is not easy, but it is made far more difficult by the utter lack of a national consensus that these are the foods responsible for diabetes and obesity. Stopping smoking is hard too, but once it became a national imperative, usage plummeted. In my experience, when patients are told the truth (“Stop eating carbs or your disease will progress and you may die”), they can change their behavior. And they feel empowered.Take the case of Jemia Keshwani, a 40-year-old LaGrange, Georgia, woman who has had diabetes for 25 years, and who narrowly escaped amputation of her right foot after her doctor prescribed a low-carbohydrate diet. She has lost 120lb (54kg) and no longer shoots insulin into her belly four times a day. “I didn’t understand you could change things around if you eat the right foods,” she said. “You know how sometimes you feel helpless? Now I don’t feel that way.”Or the case of Ajala Efem, a 47-year old Bronx woman, who, according to a recent article in Medscape, lost nearly 30lbs and got off 15 medications after her Bronx-based healthcare provider, OwnaHealth, prescribed a low-carb diet.“I went from being sick to feeling so great,” she told her endocrinologist. “My feet aren’t hurting; I’m not in pain; I’m eating as much as I want, and I really enjoy my food so much.”This past March, Harris asked an audience in Las Vegas how many people had family members living with diabetes. “A sea of hands went up,” she wrote on her Facebook page.Harris clearly understands the diabetes scourge and needs only a gentle push to make it a priority. So here is one final word of affectionate advice. The next time she attends a state fair, she might consider having one of those cheeseburgers she loves. It’s delicious, nutritious and will make a great photo op.Just lose the ketchup and bun.

      Neil Barsky, a former Wall Street Journal reporter and investment manager, is the founder of the Marshall Project More

    • 150 Shares169 Views

      in Elections

      Some States Say They Can’t Afford Ozempic and Other Weight Loss Drugs

      by

      Public employees in West Virginia who took the drugs lost weight and were healthier, and some are despondent that the state is canceling a program to help pay for them.Joanna Bailey, a family physician and obesity specialist, doesn’t want to tell her patients that they can’t take Wegovy, but she has gotten used to it.Around a quarter of the people she sees in her small clinic in Wyoming County would benefit from the weight-loss medications known as GLP-1s, which also include Ozempic, Zepbound and Mounjaro, she says. The drugs have helped some of them lose 15 to 20 percent of their weight. But most people in the area she serves don’t have insurance that covers the cost, and virtually no one can afford sticker prices of $1,000 to $1,400 a month.“Even my richest patients can’t afford it,” Dr. Bailey said. She then mentioned something that many doctors in West Virginia — among the poorest states in the country, with the highest prevalence of obesity, at 41 percent — say: “We’ve separated between the haves and the have-nots.”Such disparities sharpened in March when West Virginia’s Public Employees Insurance Agency, which pays most of the cost of prescription drugs for more than 75,000 teachers, municipal workers and other public employees and their families, canceled a pilot program to cover weight-loss drugs.Some private insurers help pay for medications to treat obesity, but most Medicaid programs do so only to manage diabetes, and Medicare covers Wegovy and Zepbound only when they are prescribed for heart problems.Over the past year, states have been trying, amid rising demand, to determine how far to extend coverage for public employees. Connecticut is on track to spend more than $35 million this year through a limited weight-loss coverage initiative. In January, North Carolina announced that it would stop paying for weight-loss medications after forking out $100 million for them in 2023 — 10 percent of its spending on prescription drugs.We are having trouble retrieving the article content.Please enable JavaScript in your browser settings.Thank you for your patience while we verify access. If you are in Reader mode please exit and log into your Times account, or subscribe for all of The Times.Thank you for your patience while we verify access.Already a subscriber? Log in.Want all of The Times? Subscribe. More